Gene Editing
CRISPR knockout of NRF2 re-sensitizes drug‑resistant lung tumors in preclinical study
Сообщено ИИ Изображение, созданное ИИ Проверено фактами
Researchers at ChristianaCare’s Gene Editing Institute report that disabling the NRF2 gene with CRISPR restored chemotherapy sensitivity in models of squamous non‑small cell lung cancer and slowed tumor growth, with benefits seen even when only a fraction of tumor cells were edited. The work was published online November 13, 2025 in Molecular Therapy Oncology.
Chinese scientist He Jiankui, who served time in prison for creating the world’s first gene-edited babies, now intends to pursue similar work to combat Alzheimer’s disease. He has criticized Silicon Valley’s efforts in the field as a “Nazi eugenic experiment.” This development revives ethical debates in biotechnology.
Сообщено ИИ
Scientists have used CRISPR to modify the fungus Fusarium venenatum, creating a strain that produces protein faster and with fewer emissions. The engineered version, named FCPD, reduces sugar use by 44% and grows 88% quicker than the original. It offers a more digestible and environmentally friendly alternative to traditional meat.